LaVoieHealthScience Blog

O’Dwyer’s PR News: “The Biopharma Communications Balancing Act”

The Biopharma Communications Balancing Act

LaVoieHealthScience President and CEO, Donna LaVoie, contributed to the O’Dwyer’s PR News Magazine October issue focused on healthcare and medical public relations. Donna discusses what makes strategic communications and investor relations in biotech different from other industries. The communications function is often reliant on the entire strategic leadership team in a startup biotech. From her experience, Donna explains how nuances in biotech communications require a unique skillset to articulate a scientific and clinical/commercial story while balancing important strategic imperatives like time sensitive information and regulatory processes.

Read the full article on the O’Dwyer’s PR News website.

LaVoieHealthScience offers integrated communications in life sciences, with specializations in strategy consultinginvestor relations and corporate communications, and public relations and marketing.

Featured Event

No Events

Recent Blog Posts

2021 Preview: A 360-Degree Global Market View

The “2021 Preview: A 360 Degree Global Market View,” virtual webinar was designed to discuss global market trends on public and private United States, Europe, and China markets, JPM virtual week in January 2021, and more. Panelists, including myself as moderator,...

5 Tips for 2021 Virtual Conferences

As we continue with virtual conferences in 2021, here are some tips to help you navigate the digital format and reach your target stakeholders at this year’s virtual conferences. Take advantage of one-on-one partnering systems offered by the conference to get a head...

A Well-Honed Message Will Give You the Edge You Need

The SARS-CoV-2 pathogen has scrambled literally everything around the world, including financial markets and the world economy.  At the same time, the biotech and pharmaceutical industries are in the spotlight as never before as nations and companies push...